India Supreme Court: Centre Proposes Pharma Marketing Panel For Statutory Framework

• The Centre has proposed a three-member panel to the India Supreme Court to recommend a statutory framework for regulating unethical pharmaceutical marketing.
• The proposed panel is expected to submit its report within two months, after which the Supreme Court will consider its recommendations.
• Petitioners, including FMSRAI, questioned the delay, noting a similar committee was mentioned by the Centre in 2022.
• Until a new framework is established, the voluntary Uniform Code for Pharmaceutical Marketing Practices (UCPMP) 2024 will remain in effect.
• The Supreme Court has previously expressed concerns about the UCPMP's lack of statutory backing and effective enforcement mechanisms.

This development signals a potential shift from the current voluntary UCPMP 2024 to a legally enforceable statutory framework for marketing practices, necessitating a proactive review of existing compliance protocols for drug company marketing compliance India.

The India Supreme Court recently heard arguments regarding the regulation of unethical marketing practices within the pharmaceutical industry, with the Centre proposing the formation of a three-member panel. This proposed panel is tasked with examining and recommending a statutory framework designed to curb such practices, particularly those aimed at influencing or luring medical professionals. The Centre, represented by Solicitor General Tushar Mehta, informed the Bench of Justices Vikram Nath and Sandeep Mehta that extensive discussions among relevant authorities had taken place, highlighting a clear need to strengthen the existing regulatory mechanisms.

During the proceedings, the Centre requested a two-month period for the proposed committee to conduct its examination and submit a comprehensive report. This report would then be presented to the Supreme Court for its consideration and ultimate approval. The government's submission indicated that the committee's mandate includes determining whether a statutory framework is indeed necessary and, if so, outlining its precise form to ensure that drug companies adhere to ethical marketing standards. However, the Court sought clarification on whether this proposed committee had actually been constituted, with the Centre's counsel stating he would seek instructions on the matter. The Centre also emphasized the multi-ministerial nature of the issue, requiring inter-ministerial deliberation.

Petitioners, including the Federation of Medical and Sales Representatives Associations of India (FMSRAI), have brought these concerns before the Supreme Court, seeking an effective mechanism to regulate unethical pharmaceutical marketing. Senior Advocate Sanjay Parikh, representing the petitioners, voiced strong concerns about the protracted delays in establishing a robust regulatory system. He pointed out that the Centre's own counter-affidavit from September 2022 had previously stated that a high-level committee, led by a NITI Aayog health sector member, had already been formed to explore a legally enforceable framework for pharmaceutical marketing practices.

Parikh highlighted that nearly four years had elapsed since that earlier undertaking, and the Centre was now proposing yet another three-member committee. He further noted that the Uniform Code for Pharmaceutical Marketing Practices (UCPMP) 2014 and its 2024 iteration are substantially similar, with the latter primarily featuring changes related to headings and minor corrections. The Centre's current stance is that the UCPMP 2024 will continue to govern the field until the newly proposed committee submits its report and a decision is made on its recommendations.

The Supreme Court itself has previously expressed reservations about the UCPMP 2024 enforcement mechanism, questioning its adequacy in regulating drug companies. The Court had also raised doubts about the Centre's intention to provide statutory backing to the code, observing that without effective government control, a supposedly mandatory regulatory regime could effectively remain voluntary. This ongoing scrutiny underscores the critical need for a legally binding framework to ensure Indian pharmaceutical ethics regulation.

The FMSRAI petition, filed in response to "ever-increasing instances of unethical marketing practices by Pharmaceutical Companies in their dealings with healthcare professionals," seeks not only an effective regulatory mechanism but also judicial guidelines until Parliament or the government enacts an appropriate statutory framework. The Bench has now reserved its order on these petitions after considering all submissions. This development signals a potential shift from the current voluntary UCPMP 2024 to a legally enforceable statutory framework for marketing practices, necessitating a proactive review of existing compliance protocols for drug company marketing compliance India.

Compliance officers and legal counsel in the Indian pharmaceutical sector must closely monitor the Supreme Court's upcoming order and the progress of the proposed 3-member panel. This development signals a potential shift from the current voluntary UCPMP 2024 to a legally enforceable statutory framework for marketing practices, necessitating a proactive review of existing compliance protocols to mitigate future risks.

Source: Original reporting via legal news sources.